Over the past two weeks, there's been a 6.3% jump in cases, according to the CDC. The past week saw an increase of 7.1% in test positivity. The news is a boon for Moderna, BioNTech and Novavax.

Novavax shares fell 11.2% during Wednesday's session. Vaccine stocks are volatile after the first US bird flu death and a CDC report on rising respiratory illnesses. Get Wall Street's Hottest ...

Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine ... the latest respiratory illness data announced by the CDC last week. Pfizer (PFE) and BioNTech (BNTX), the developers of the ...

Novavax's vaccine is included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on Ju Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein ...

Novavax shares are trading higher by 13.5% during Tuesday's session. A recent CDC report highlights a sharp increase in respiratory illnesses across the United States. Additionally, the Louisiana ...

Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day. The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in ...